A ballot from the well being coverage nonprofit KFF discovered that 1 in 8 adults say they’ve taken a GLP-1 agonist, the weight problems and diabetes drugs that embrace Ozempic, Mounjaro and Zepbound.
Amongst these surveyed, 12 % mentioned that they had used a GLP-1 agonist, with 6 % saying they’re at present utilizing one. The bulk — 62 % — of them mentioned they had been utilizing the medication to deal with a continual situation similar to diabetes or coronary heart illness, whereas the remaining 38 % they took the drugs simply to drop pounds.
Of the individuals with diabetes, 4 out of 10 mentioned that they had used a GLP-1 agonist.
GLP-1 agonists are indicated for treating individuals who have diabetes, weight problems or are liable to heart problems associated incidents. The medication’ off-label use for beauty weight reduction has sparked widespread curiosity.
Consciousness of those medication gave the impression to be comparatively excessive, with a 3rd saying they’d heard “quite a bit” in regards to the drugs and 27 % saying they’d heard “some.” Older, wealthier adults and people with continual sicknesses had been extra prone to have heard one thing about GLP-1 agonists.
About 80 % mentioned they received a GLP-1 agonist by way of their major care supplier or a specialist. One other 23 % mentioned they received the medication from both a web based supplier, a medical spa or “someplace else.”
A number of GLP-1 agonists — together with Ozempic, Mounjaro and Trulicity — are at present in scarcity, with the Meals and Drug Administration reporting the rationale as a rise in demand.
Survey individuals had been additionally requested whether or not they believed Medicare ought to cowl GLP-1 agonists. The federal well being care program is barred from masking weight reduction drugs, although the latest approval of the load loss drug Wegovy for heart problems now means Medicare beneficiaries can entry the drug.
A earlier KFF evaluation indicated that as many as 1 in 4 beneficiaries who’ve weight problems may get Weogvy following its expanded approval.
In whole, 61 % mentioned Medicare ought to cowl GLP-1 agonists to deal with weight problems. Their opinions remained successfully unchanged after being instructed the arguments Medicare towards masking weight problems drugs, similar to the chance that premiums may go up or that the protection would place monetary pressure on the federal government program.
The KFF survey was performed between April 23 and Could 1 amongst a pattern of 1,479 U.S. adults.
Copyright 2024 Nexstar Media Inc. All rights reserved. This materials will not be revealed, broadcast, rewritten, or redistributed.
